Oral Isobutyramide Therapy in Patients with Thalassemia Intermedia: Results of a Phase II Open Study
- 29 February 2000
- journal article
- clinical trial
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 26 (1) , 105-111
- https://doi.org/10.1006/bcmd.2000.0283
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The β-ThalassemiasNew England Journal of Medicine, 1999
- NOVEL TREATMENT OPTIONS IN THE SEVERE β‐GLOBIN DISORDERSBritish Journal of Haematology, 1995
- Survival in Medically Treated Patients with Homozygous β-ThalassemiaNew England Journal of Medicine, 1994
- Beta-thalassemia unlinked to the beta-globin gene in an English familyBlood, 1993
- Butyrate-induced reactivation of the fetal globin genes: A molecular treatment for theβ-hemoglobinophatiesCellular and Molecular Life Sciences, 1993
- Therapeutic Approaches to Hemoglobin Switching in Treatment of HemoglobinopathiesAnnual Review of Medicine, 1992
- Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching.Proceedings of the National Academy of Sciences, 1988
- Pharmacological Manipulation of Fetal Hemoglobin Synthesis in Patients with Severe β‐ThalassemiaAnnals of the New York Academy of Sciences, 1985
- Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate.Proceedings of the National Academy of Sciences, 1984
- Interaction between Homozygous β0 Thalassaemia and the Swiss Type of Hereditary Persistence of Fetal HaemoglobinBritish Journal of Haematology, 1981